Post-marketing surveillance in Taiwan ensures ongoing drug safety by monitoring adverse events and effectiveness after market entry. The TFDA requires pharmaceutical companies to submit Periodic Safety Update Reports (PSURs) and conduct pharmacovigilance activities. If necessary, additional studies or labeling changes may be mandated based on real-world data to mitigate risks and protect public health.
